ONCY: the cash flow

MyFinsight

For the quarter ending 2026-03-31, ONCY had $291K increase in cash & cash equivalents over the period. -$7,299K in free cash flow.

Cash Flow	2026-03-31	2025-12-31
Net loss	-9,243	-28,759
Depreciation of property and equipment	16	70
Non-cash lease expense	73	288
Stock-based compensation expense	2,299	3,104
Value of shares issued to consultants	730	3,467
Unrealized foreign exchange loss	-13	137
Change in fair value of warrant derivative	0	-153
Fair value loss from sepa arrangement	-	-388
Value of shares issued for sepa arrangement commitment fees	-	440
Other receivables	388	-3
Prepaid expenses	155	-580
Accounts payable	-813	2,932
Accrued liabilities	249	-360
Pancreatic cancer action network (pancan) receivables and payables	-	-1,682
Operating lease liabilities	-74	-293
Net cash used in operating activities	-7,293	-20,112
Acquisition of property and equipment	6	6
Net cash used in investing activities	-6	-6
Proceeds from exercise of warrant derivative	-	0
Proceeds from issuance of common stock-At The Market Offering Agreement	-	11,767
Proceeds from issuance of common stock-Standby Equity Purchase Agreement	-	2,348
Proceeds from stock option exercise	-	32
Other	-	-27
Proceeds from at-the-market offering agreements, net of issuance costs	7,614	-
Net cash provided by financing activities	7,614	14,120
Effect of exchange rate changes on cash and cash equivalents	-24	121
Net increase (decrease) in cash and cash equivalents	291	-5,877
Cash and cash equivalents, beginning of period	5,202	11,079
Cash and cash equivalents, end of period	5,493	5,202

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.